socaltech.com
Los Angeles-based
Appia Bio, a biotech startup focused on developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, has launched from stealth mode, saying it has raised $52M in a Series A funding round. The funding was led by 8VC, and also included Two Sigma Ventures, Sherpa Healthcare Partners and Freeflow Ventures. The company said its technology was originally developed in the laboratory of Lili Yang, PhD, associate professor at University of California, Los Angeles (UCLA). Appia said that Francisco Gimenez, PhD, and David Moskowitz, PhD, of 8VC, both join the company s board, with David Baltimore, PhD, of the California Institute of Technology (Caltech) serving as Chairman. The company said the proceeds from the funding will go to support advancement of its therapy candidates.
Making sense of the markets this week: May 10, 2021
By Dale Roberts on May 7, 2021
Celebrity investors help push Wealthsimple s valuation even higher into the stratosphere; U.S. stocks thrive on pessimism; why rental companies are buying used cars; and will the Gates split rock the markets?
Advertisement
Photo by Obi Onyeador on Unsplash
Each week, Cut the Crap Investing founder Dale Roberts shares financial headlines and offers context for Canadian investors.
Advertisement
Wealthsimple taps celebrities and nets a $5-billion valuation
In October of 2020, we reported on a previous round of financing for Wealthsimple. At that time, valuation estimates for the Canadian online investment company were in the $1-billion range.
Timescale Raises $40M Series B as Cloud Adoption of Its Database Accelerates – Consumer Electronics Net consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
While the growth of big data and analytics help businesses understand their customers, serve better ads, and sell more, in healthcare, these same methodologies and technologies have a real enduring, profound societal impact. Real-world data (RW) and real-world evidence (RWE), made possible by technology, are being used by pharmaceutical companies and the healthcare ecosystem to develop, evaluate, implement, and optimize new treatment approaches. Aetion is the RWD and RWE platform that enables the healthcare system to harness the power of data to shape the future of medicine. The platform is designed to accelerate the time to market without compromising scientific rigor. For example, the company partnered with the FDA to develop real-world analytics related to COVID and vaccines. AlleyWatch caught up with CEO Carolyn Magill to learn more about Aetion’s approach to RWD is enabling the healthcare system to make informed decisions, the company’s strategic, plans, latest round of fun
This Week in Apps: An Apple event, more Clubhouse clones and an app store antitrust hearing
Welcome back to This Week in Apps, the weekly TechCrunch series that recaps the latest in mobile OS news, mobile applications and the overall app economy. The app industry is as hot as ever, with a record 218 billion downloads and $143 billion in global consumer spend in 2020.
Consumers last year also spent 3.5 trillion minutes using apps on Android devices alone. And in the U.S., app usage surged ahead of the time spent watching live TV. Currently, the average American watches 3.7 hours of live TV per day, but now spends four hours per day on their mobile devices.